Table 3.
Mode of therapy in patients with multiresistant pathogens by site of infection (patients with evaluable treatment outcome; n = 215)
| Proportion of patients, % (n) | Monotherapy | Combination therapy |
|---|---|---|
| Total MRB population | 65.1 % (140) | 34.9 % (75) |
| Intraabdominal infection (cIAI) | 28.6 % (40) | 40.0 % (30) |
| Skin and soft tissue infection (cSSTI) | 31.4 % (44) | 14.7 % (11) |
| Diabetic foot infection (DFI) | 19.3 % (27) | 4.0 % (3) |
| Community-acquired pneumonia (CAP) | 8.6 % (12) | 1.3 % (1) |
| Hospital-acquired pneumonia (HAP) | 13.6 % (19) | 14.7 % (11) |
| Blood stream infection (BSI) | 12.9 % (18) | 5.3 % (4) |
| Multiple-site infection (MSI) | 9.3 % (13) | 18.7 % (14) |
Patients could have more than one MRB; 2 patients with HAP were diagnosed with BSI as well, these were not categorized as MSI because the lung infection was regarded as the focus of BSI